SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust ($SLV) is experiencing intense bullish momentum, driven by spot silver prices reaching new all-time highs. This rally is fueled by tightening global supply due to upcoming Chinese export restrictions, alongside booming industrial demand from EV batteries, solar, and AI data centers. The community is actively discussing a potential 'silver squeeze' and a significant re-rating of silver's value, though some anticipate a near-term pullback after its rapid ascent.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors celebrate the recent FDA approval of YARTEMLEA, the first and only treatment for a life-threatening post-transplant complication, sparking a fervent discussion on its potential. The community believes the stock is significantly undervalued, pointing to a strategic partnership with Novo Nordisk and a strong pipeline, fueling speculation of a massive short squeeze and potential buyout. Anticipation is high for further details on commercialization plans and pricing, with many urging long-term holds.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is trending amidst significant network upgrades, including the rollout of Polkadot 2.0 featuring elastic scaling, a new supply cap for DOT with halving emissions, and a migration of governance and staking to its Asset Hub chain. Community sentiment is notably divided, with proponents viewing these tokenomic shifts as strong bullish catalysts for long-term growth and others expressing deep skepticism regarding past performance and future prospects. These developments also unfold alongside discussions of its interoperability within the broader crypto ecosystem and ongoing dialogues around potential crypto ETF approvals.

abrdn ETF - abrdn Physical Platinum Shares ETF

abrdn Physical Platinum Shares ETF (PPLT) is experiencing a notable surge in trading volume and price, fueled by strong community sentiment anticipating a significant breakout. Discussions highlight platinum's projected supply deficits, rising industrial demand for automotive catalysts and green energy, and its perceived undervaluation relative to gold. This bullish outlook is further intensified by geopolitical risks affecting key mining regions.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is a major talking point in the drone sector, propelled by the FCC's recent ban on foreign-made drones and the passage of the NDAA, both signaling increased opportunities for US manufacturers. The community is actively debating the potential for significant defense contracts, especially for its Black Widow platform and emerging unmanned surface vessels, though some express skepticism about revenue timelines and management's communication given previous expectations.

Enbridge, Inc. engages in the provision of gas and oil. It operates through the following segments: Liquid Pipelines, Gas Distribution and Storage, Gas Transmission and Midstream, Renewable Power Generation, and Energy Services. The Liquids Pipelines segment consists of common carrier and contract crude oil, natural gas liquids and refined products pipelines and terminals in Canada and the U.S., including Canadian Mainline, Regional Oil Sands System, Southern Lights Pipeline, Spearhead Pipeline, Seaway Crude Pipeline interest, and other feeder pipelines. The Gas Distribution & Storage segment consists of natural gas utility operations, the core of which is Enbridge gas, which serves residential, commercial and industrial customers. It also includes natural gas distribution activities in Quebec and an investment in Noverco, which holds a majority interest in a subsidiary entity engaged in distribution and energy transportation primarily in Quebec. The Gas Transmission & Midstream segment consists of investments in natural gas pipelines, processing and green energy projects, the company's commodity marketing businesses, and international activities. The Renewable Power Generation segment consists primarily of investments in wind and solar power generating assets, as well as geothermal, waste heat recovery, and transmission assets. The Energy Services segment consists of businesses in Canada and the United States including logistical services, refinery supply services and the firm's volume commitments on various pipeline systems. The company was founded on April 30, 1949 and is headquartered in Calgary, Canada.

Enbridge Inc

Enbridge is trending amid recent positive legal and regulatory developments concerning its critical pipeline infrastructure, which is easing political uncertainties. The community is focused on the company's consistent dividend growth and strategic initiatives, including major acquisitions and new ventures designed to capitalize on increasing natural gas demand from data centers and LNG exports. Investors are evaluating Enbridge's long-term stability and growth prospects within the evolving energy landscape.

Ecolab, Inc. engages in providing products and services in the field of water, hygiene, and energy. It operates through the following segments: Global Industrial, Global Institutional and Specialty, Global Healthcare and Life Sciences, Global Pest Elimination, and Corporate. The Global Industrial segment relates to water, food and beverage, paper, and downstream operating segments. The Global Institutional and Specialty segment refers to the institutional, specialty, and healthcare operating segments. The Global Healthcare and Life Sciences segment includes the healthcare and life sciences operations. The Global Pest Elimination segment provides services designed to detect, prevent and eliminate pests, such as rodents and insects, in full-service and quick-service restaurants, food and beverage processors, hotels, grocery operations, and other. The company was founded by Merritt J. Osborn in 1923 and is headquartered in St. Paul, MN.

Ecolab, Inc.

Ecolab is trending as it strategically expands into high-tech water solutions for the semiconductor and AI data center sectors, launching new cooling technologies. This move, coupled with recent analyst upgrades and strong earnings performance, has the community actively discussing its potential as a reliable long-term growth story focused on innovation and sustainability.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) is currently trending as investors eagerly anticipate upcoming monthly dividend payouts, often citing them as a reliable source of income. The community actively debates JEPQ's performance and tax efficiency against similar covered-call ETFs, with many viewing recent price dips as attractive buying opportunities for long-term retirement portfolios. Its strategy of generating income from Nasdaq-listed equities continues to appeal to those seeking steady distributions amid broader market fluctuations.

Global X Funds - Global X Silver Miners ETF

Global X Silver Miners ETF ($SIL) is trending as silver prices surge to new highs, driven by robust industrial demand in sectors like solar, EVs, and AI, alongside ongoing supply deficits. Despite the metal's strong rally, community discussions highlight frustration over miners' perceived underperformance, with many anticipating a significant "catch-up" rally to align with silver's bullish momentum and long-term potential.

Direxion Shares ETF Trust - Direxion Daily S&P 500 Bull 3X Shares

Direxion Daily S&P 500 Bull 3X Shares

Direxion Daily S&P 500 Bull 3X Shares is trending as the broader S&P 500 index recently achieved new record highs, fueling fervent bullish sentiment. The community is actively debating whether this marks the continuation of an upward rally, prompting many to buy dips and leverage for amplified gains. While economic indicators and discussions around central bank policies add context, traders are keenly focused on riding the market's momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of BrainStorm Cell Therapeutics slipped in after-hours trading Thursday after the company said&nbsp;it has been removed from the Nasdaq Capital Market for falling short of minimum equity requirements.The stock will stop trading on Nasdaq when&nbsp;the&nbsp;markets open Friday.&nbsp;Brainstorm Cell’s stock plunged 42.7% in after-hours trading on Thursday, falling to $0.67, following a 2.5% dip during the regular session.The company said it has received approval to shift its listing to the OTCQB Venture Market, where it will continue trading under the same ticker.“While this delisting is a difficult outcome, it does not change our core mission or our dedication to the ALS community,” said CEO Chaim Lebovits. “Our move to the OTCQB ensures trading continuity and allows us to maintain focus on advancing NurOwn.”NurOwn is BrainStorm’s experimental cell therapy for ALS, a progressive disease that steadily weakens muscles and shortens lives.&nbsp;The company is preparing to launch a pivotal Phase 3b trial, designed in coordination with the FDA under a Special Protocol Assessment agreement.In June, BrainStorm released new survival data from 10 ALS patients who received NurOwn through its Expanded Access Program.The company reported that 90% of those patients survived more than five years from symptom onset, marking a significant contrast to the roughly 10% survival rate reported in the general ALS population.&nbsp;The median survival was 6.8 years, with the only death attributed to elective euthanasia.To support the upcoming trial, BrainStorm recently entered a manufacturing agreement with Minaris Advanced Therapies, a U.S.-based contract development and manufacturing organization.&nbsp;It has also partnered with Israel-based Pluri to expand clinical supply capabilities.The company stated that the Nasdaq delisting will not affect its business operations, R&amp;D activities, or its commitment to shareholders.On Stocktwits, retail sentiment for Brainstorm was ‘bullish’ amid ‘high’ message volume.One user said that BrainStorm can possibly tap the at-the-market (ATM) facility to fund its upcoming trial, citing the stock’s rebound.<stembedurl>https://stocktwits.com/steven_glandsberg/message/621369650</stembedurl>Another user saw the dip as a buying opportunity, calling it a “good buy time.”<stembedurl>https://stocktwits.com/bigdave100/message/621361783</stembedurl><a href="https://stocktwits.com/symbol/BCLI">Brainstorm’s stock</a> has declined 45.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a man walking in front of the Nasdaq building at Times Square in New York. (Photo by John Smith/VIEWpress)

BrainStorm Cell Therapeutics Crashes After Hours On Nasdaq Delisting Notice; Retail Sees 'Buy Time'

Shares of BrainStorm Cell Therapeutics slipped in after-hours trading Thursday after the company said it has been removed from the Nasdaq Capital Market for falling short of minimum equity requirements.

Equity

The company plans to move its shares to the OTCQB market and says the delisting won't impact its ALS research or upcoming Phase 3b trial. 

BrainStorm Cell Therapeutics saw rising retail chatter Monday when it obtained FDA clearance for Phase 3b clinical trials of NurOwn, its amyotrophic lateral sclerosis (ALS) stem cell therapy candidate.Through a Special Protocol Assessment (SPA), the FDA confirmed that the study design and statistical methodology meet regulatory standards required for future BLAs.The company’s shares closed up 3.03% at $1.36 on Monday but slipped 12.54% to $1.19 in after-hours trading.BrainStorm CEO Chaim Lebovits said the FDA approval allows the company to commence operations at clinical sites while it pursues funding through multiple sources, such as non-dilutive grants.The clinical Phase 3b trial aims to enroll around 200 ALS patients from leading academic institutions.&nbsp;A 24-week double-blind placebo-controlled trial will initiate the study before moving into a 24-week open-label extension, during which all patients receive NurOwn.&nbsp;Researchers will assess the primary outcome by measuring the change in ALSFRS-R scores from baseline to week 24.Completing Phase 3 research allows NurOwn to hold Orphan Drug status concurrently in the United States and the European Union.&nbsp;Meanwhile, the U.S. Patent Office approved BrainStorm's intellectual property rights to develop an allogeneic exosome-based platform.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 31,000% surge in 24-hour message volume.Some traders pointed to the company’s pursuit of private grants or potential partnerships, with names like Johns Hopkins University and Pfizer mentioned as speculative collaborators, as key bullish drivers.<stembedurl>https://stocktwits.com/Whealthy/message/615149075</stembedurl>Others noted the heavy intraday volume, which reached 58 million shares, expressing frustration over the lack of price movement during regular hours.&nbsp;Still, optimism remained for a possible after-hours push or improved action in the following session, with hopes for reduced resistance ahead.<stembedurl>https://stocktwits.com/Kojak3/message/615151221</stembedurl>The stock has declined 36.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Physical Therapy for the Elderly Caused by Amyotrophic Lateral Sclerosis. Asian home nurse helping a senior woman while doing physical therapy on her patient outdoors. Photo credit: Getty Images

Retail Bulls Cheer FDA Clearance For BrainStorm’s ALS Therapy, But Shares Dip After Hours

BrainStorm Cell Therapeutics plans to enroll 200 ALS patients in its FDA-cleared Phase 3b trial of NurOwn, with a 24-week double-blind phase followed by an open-label extension.

WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters.&nbsp;Our focus is on quality, liquid, growth-oriented, and under-followed companies in sectors actively drawing in capital such as AI, blockchain, biotech and consumer.&nbsp;This real-time news surveillance and targeting combined with our proprietary 5-point analysis, aids in uncovering stocks poised for powerful multi-day or multi-month moves—often long before Wall Street analysts catch on.&nbsp;Here’s what we’re keeping our eyes on:<h3>1. Purple Biotech (NASDAQ: PPBT)</h3>Background: Purple Biotech is a clinical-stage oncology company that aims to redefine cancer treatment through its innovative approaches targeting tumor immune evasion and drug resistance. Its lead product, CM24, is a first-in-class anti-CEACAM1 antibody being developed to treat pancreatic and other aggressive cancers. The oncology space, worth billions, continues to see intense investor interest, especially as companies explore biomarker-driven therapies.The News: Purple Biotech unveiled final Phase 2 results showing CM24 combined with nivolumab and chemotherapy significantly improved overall survival (OS) and progression-free survival (PFS) in pancreatic cancer patients with specific biomarkers. The data revealed a 79% reduction in death risk and a 5.1-month OS improvement, particularly in biomarker-enriched patient groups.What It Means: These results not only validate CM24’s potential but also position Purple Biotech to expand its pipeline into broader cancer applications. With a planned Phase 2b trial targeting high-CEACAM1 patients, the company is tapping into precision oncology—a sector that continues to draw investor enthusiasm due to its game-changing potential.Stock Reaction: PPBT skyrocketed 151%, reflecting the market’s recognition of this major milestone in the fight against pancreatic cancer.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_23_40_AM_19763a2e26.png" alt="Screenshot 2024-12-05 at 2.23.40 AM.png">&nbsp;<hr>&nbsp;<h3>2. Stereotaxis (NYSE: STXS)</h3>Background: Stereotaxis is at the forefront of surgical robotics, specializing in robotic magnetic navigation (RMN) systems for minimally invasive endovascular interventions. Its GenesisX system aims to improve precision, safety, and efficiency in procedures, a critical innovation as the global market for robotic-assisted surgeries is projected to grow at a double-digit CAGR over the next decade.The News: The GenesisX robotic system was showcased for the first time at the RSNA 2024 Annual Meeting, in collaboration with Neusoft Medical Systems. The partnership aligns GenesisX with advanced imaging technologies, offering enhanced capabilities for healthcare providers worldwide.What It Means: The exposure at RSNA, one of the largest radiology conferences globally, strengthens Stereotaxis' visibility and positions the GenesisX as a next-generation tool for minimally invasive surgeries. This partnership could unlock new revenue streams as the healthcare sector increasingly adopts robotic solutions.Stock Reaction: STXS edged up 4.18%, with investors optimistic about the long-term implications of the GenesisX system.Stocktwits.com Sentiment &amp; Popularity:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_25_09_AM_6fecf5b145.png" alt="Screenshot 2024-12-05 at 2.25.09 AM.png">&nbsp;<hr>&nbsp;<h3>3. Delcath Systems (NASDAQ: DCTH)</h3>Background: Delcath Systems focuses on innovative therapies for primary and metastatic liver cancers. Its flagship product, HEPZATO KIT™, offers a unique approach to delivering high-dose chemotherapy directly to the liver while minimizing systemic exposure. This precision is critical for targeting liver-dominant diseases—a market that represents tens of thousands of patients annually.The News: The FDA has cleared Delcath’s Phase 2 trial of HEPZATO in liver-dominant metastatic colorectal cancer. The study will compare HEPZATO plus standard chemotherapy with chemotherapy alone, aiming to validate its safety and efficacy in this high-need population.What It Means: HEPZATO has already shown promise in metastatic uveal melanoma, and this expansion could significantly broaden its market reach. The ability to address liver-dominant cancers positions Delcath as a potential leader in a niche but high-value market.Stock Reaction: DCTH rose 6.4% on the day, continuing its strong performance following a 203% year-to-date rally.&nbsp;&nbsp;<hr>&nbsp;<h3>4. BrainStorm Cell Therapeutics (NASDAQ: BCLI)</h3>Background: BrainStorm is a pioneering biotech company developing autologous adult stem cell therapies for neurodegenerative diseases like ALS and progressive MS. Its lead candidate, NurOwn®, is designed to deliver neurotrophic factors directly to damaged neurons, potentially altering the course of these debilitating diseases. With few effective therapies for ALS, the market is ripe for disruptive innovation.The News: BrainStorm announced a December 11 webinar featuring updates on its Phase 3b trial of NurOwn, aimed at refining the therapy’s efficacy for FDA approval. This comes as the company prepares for a pivotal registrational trial.What It Means: If successful, NurOwn could be the first significant breakthrough for ALS in years, addressing an unmet medical need in a multibillion-dollar market. The company’s focus on early-stage ALS patients may improve trial outcomes and strengthen its case for regulatory approval.Stock Reaction: BCLI dipped 2.66%, reflecting cautious investor sentiment as the market awaits trial data.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_26_15_AM_28681ca8de.png" alt="Screenshot 2024-12-05 at 2.26.15 AM.png">&nbsp;<hr>&nbsp;<h3>5. DMG Blockchain Solutions (OTCQB: DMGGF)</h3>Background: DMG Blockchain integrates Bitcoin mining with sustainability and AI-driven data centers. Its Terra Pool initiative is designed to create a carbon-neutral Bitcoin mining ecosystem, catering to ESG-conscious investors and industries. With institutional adoption of Bitcoin accelerating, DMG’s dual focus on growth and environmental responsibility makes it a standout.The News: DMG reported November mining results of 32 BTC, an increased hashrate of 1.66 EH/s, and significant insider purchases by its CEO and COO. The company also secured $17.3 million to fund growth initiatives, including AI and blockchain infrastructure.What It Means: The raised capital and insider purchases signal confidence in DMG’s ability to scale operations and align with Bitcoin’s anticipated market growth. The focus on sustainability could attract institutional players prioritizing ESG compliance.Stock Reaction: DMGI remained stable dipping just slightly, with the market digesting the long-term growth potential from recent investments.&nbsp;<hr>&nbsp;<h3>6. BriaCell Therapeutics (NASDAQ: BCTX)</h3>Background: BriaCell specializes in novel immunotherapies targeting advanced breast cancer. Its lead therapy, Bria-IMT™, is designed to boost the immune system's response against tumors. With metastatic breast cancer affecting over 2 million women globally, there’s an urgent need for effective treatments.The News: BriaCell’s pivotal Phase 3 study of Bria-IMT received a positive safety review from the DSMB, allowing the trial to proceed without changes. The trial is being conducted under the FDA’s Fast Track Designation.What It Means: The DSMB’s approval reinforces Bria-IMT’s safety and paves the way for the company to potentially deliver a game-changing therapy for metastatic breast cancer patients. The Fast Track Designation further emphasizes its potential impact.Stock Reaction: BCTX shares soared 13%, reflecting growing investor confidence in the company’s clinical progress.Rumours from Twitter:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_27_31_AM_e685b0a306.png" alt="Screenshot 2024-12-05 at 2.27.31 AM.png">&nbsp;&nbsp;<h3>7. Laser Photonics Corporation (NASDAQ: LASE)</h3>Background: Laser Photonics Corporation specializes in industrial laser systems, providing innovative solutions for cleaning, material processing, and now pharmaceuticals. With its recent acquisition of Control Micro Systems, Inc., the company is expanding into new sectors, including the fast-growing pharmaceutical and semiconductor industries. The industrial laser market, driven by advances in automation and precision engineering, is projected to exceed $10 billion by 2030, making it a hotbed for innovation.The News: Laser Photonics announced the successful installation of a state-of-the-art pill drilling system at a customer’s facility. The system, a Class I automated CO2 laser with advanced fume extraction and machine vision inspection, is designed to streamline pill production processes. This system also doubles as an anti-counterfeiting solution, addressing critical challenges in the pharmaceutical supply chain.What It Means: This installation signifies Laser Photonics’ pivot into high-demand verticals like pharmaceuticals. By integrating advanced laser technology with automated inspection, the company is positioning itself as a key supplier in a market prioritizing efficiency, precision, and security.Stock Reaction: LASE shares declined 6.40%, reflecting broader market volatility rather than company-specific concerns. Investors appear cautiously optimistic about the company's potential in its newly targeted markets.&nbsp;Also Read:<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/featured/why-this-small-biotech-stock-could-be-primed-for-a-breakout/">&nbsp;Why This Small Biotech Stock Could Be Primed for a Breakout</a>Be the First to Know:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like&nbsp;AST SpaceMobile (NASDAQ: ASTS), which shot up&nbsp;+533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a long or short position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

News Movers: Yesterday’s Hottest News That Could Move the Needle Today

Your Only Digest of Market-Moving News and Rumours From High-Growth, Small Cap Stocks

Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.

Current Price	$0.59
Prev Close	$0.6043
Open	$0.5603
Dividend Yield	0.00%
50-Day Moving Average	$0.6325
Beta	0.76
Avg. Volume	16,534.42
PE Ratio	-0.40

52-Week High	$0.8936
52-Week Low	$0.521
Market Capitalization	$6.53M
EPS (Annual)	-$2.31
Price to Book	-0.85
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

BCLI
Brainstorm Cell Therapeutics, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BCLI News

BCLIBrainstorm Cell Therapeutics, Inc.